Similar articles

Abstract: Background and objective: Gonadotropin-releasing hormone (GnRH) plays an important role in the regulation of ovarian function and ovarian cancer cell growth. In this study, we determined whether administration of the GnRH agonist (GnRHa), triporelin, prior to cisplatin treatment affects cisplatin and/or prevents cisplatin-induced ovarian damage. Methods: nu/nu mice were injected with ovarian cancer OVCAR-3 cells intraperitoneally. After two weeks, the mice were treated with saline (control), cisplatin, GnRHa, or cisplatin plus GnRHa for four weeks. At the end of the experimental protocol, blood, tumor, ovary, and uterine tissues were resected for hematoxylin and eosin (H&E) staining, immunohistochemical analyses of Ki67, nuclear factor-κB (NF-κB), and caspase-3, transmission electron microscopy of apoptosis, or enzyme-linked immunosorbent assay (ELISA) analyses of anti-Mullerian hormone (AMH). Results: cisplatin treatment effectively inhibited tumor growth in mice treated with human ovarian cancer cells; however the treatment also induced considerable toxicity. Immunohistochemical analyses showed that Ki67 expression was reduced in cisplatin-treated mice compared to control (P<0.05), but there was no statistically significant differences between cisplatin-treated mice and cisplatin plus GnRHa-treated mice (P>0.05), while expressions of NF-κB and caspase-3 were reduced and induced, respectively, in cisplatin-treated mice and cisplatin plus GnRHa-treated mice. Apoptosis occurred in the GnRHa, cisplatin, and cisplatin plus GnRHa-treated mice, but not in control mice. Ovaries exposed to GnRHa in both GnRHa mice and cisplatin-treated mice (combination group) had significantly more primordial and growth follicles and serum levels of AMH than those in the control mice and cisplatin-treated mice (P<0.05). Conclusions: Administration of GnRHa to mice significantly decreased the extent of ovarian damage induced by cisplatin, but did not affect the anti-tumor activity of cisplatin.

[1]Arencibia, J.M., Schally, A.V., 2000. Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. Int. J. Oncol., 16(5):1009-1013.

[2]Asschert, J.G., Vellenga, E., Ruiters, M.H., de Vries, E.G., Asschert, J.G., Vellenga, E., Ruiters, M.H., 1999. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer, 82(2):244-249.

[3]Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M.P., Castronovo, V., 1994. The NF-κB transcription factor and cancer: high expression of NF-κB and IκB related proteins in tumor cell lines. Biochem. Pharmacol., 47(1):145-149.

[4]Carter, B.D., Kaltschmidt, C., Kaltschmidt, B., Offenhäuser, N., Böhm-Matthaei, R., Baeuerle, P.A., Barde, Y.A., 1996. Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75. Science, 272(5261):542-545.

[5]Danforth, D.R., Arbogast, L.K., Friedman, C.I., 2005. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil. Steril., 83(5):1333-1338.

[6]Emons, G., Schally, A.V., 1994. The use of luteinizing hormone-releasing ormone agonists and antagonists in gynecological cancers. Hum. Reprod., 9(7):1364-1379.

[7]Emons, G., Weiss, S., Ortmann, O., Grundker, C., Schulz, K.D., 2000. Luteinizing hormone-releasing hormone (LHRH) might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur. J. Endocrinol., 142(6):665-670.

[8]Emons, G., Ortmann, O., Teichert, H.M., Fassl, H., Löhrs, U., Kullander, S., Kauppila, A., Ayalon, D., Schally, A., Oberheuser, F., 1996. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer, 78(7):1452-1460.

[9]Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., Nagata, S., 1998. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 391(6662):43-50.

[10]Grilli, M., Pizzi, M., Memo, M., Spano, P., 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science, 274(5291):1383-1385.

[11]Grimm, S., Bauer, M.K., Baeuerle, P.A., Schulze-Osthoff, K., 1996. Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J. Cell Biol., 134(1):13-23.

[12]Gründker, C., Schulz, K., Günthert, A.R., Emons, G., 2000. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J. Clin. Endocrinol. Metab., 85(10):3815-3820.

[13]Gründker, C., Günthert, A.R., Westphalen, S., Emons, G., 2002a. Biology of the GnRH system in human gynecological cancers. Eur. J. Endocrinol., 146(1):1-14.

[14]Gründker, C., Günthert, A.R., Millar, R.P., Emons, G., 2002b. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J. Clin. Endocrinol. Metab., 87(3):1427-1430.

[15]Kang, S.K., Cheng, K.W., Nathwani, P.S., Choi, K.C., Leung, P.C., 2000. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine, 13(3):297-304.

[16]Kim, K.Y., Choi, K.C., Auersperg, N.K., Leung, P.C., 2006. Mechanism of gonadotropin releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr. Relat. Cancer, 13(1):211-220.

[17]Imai, A., Takagi, A., Horibe, S., Takagi, H., Tamaya, T., 1998. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J. Clin. Endocrinol. Metab., 83(2):427-431.

[18]Imai, A., Ohno, T., Iida, K., Fuseya, T., Furui, T., Tamaya, T., 1994. Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer, 74(9):2555-2561.

[19]Janssens, R.M., Brus, L., Cahill, D.J., Huirne, J.A., Schoemaker, J., Lambalk, C.B., 2000. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum. Reprod. Update, 6(5):505-518.

[20]Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J., 2008. Cancer statistics, 2008. CA: Cancer J. Clin., 58(2):71-96.

[21]Meirow, D., Lewis, H., Nugent, D., Epstein, M., 1999. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum. Reprod., 14(7):1903-1907.

[22]Meirow, D., Assad, G., Dor, J., Rabinovici, J., 2004. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum. Reprod., 19(6):1294-1299.

[23]Myers, M., Britt, K.L., Wreford, N.G., Ebling, F.J., Kerr, J.B., 2004. Methods for quantifying follicular numbers within the mouse ovary. Reproduction, 127(5):569-580.

[24]Pereira, S.G., Oakley, F., 2008. Nuclear factor-kappaB1: regulation and function. Int. J. Biochem. Cell Biol., 40(8):1425-1430.

[25]Seppänen, M., Henttinen, T., Lin, L., Punnonen, J., Grénman, S., Punnonen, R., Vihko, K.K., 1998. Inhibitory effects of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators. Oncol. Res., 10(11-12):575-589.

[26]Shibata, S., Sato, H., Ota, H., Karube, A., Takahashi, O., Tanaka, T., 1997. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Gynecol. Oncol., 66(2):217-221.

[27]Stoffel, A., Chaurushiya, M., Singh, B., Levine, A.J., 2004. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. PNAS, 101(24):9079-9084.

[28]Sun, X.F., Zhang, H., 2007. NF-κB and NF-κBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol., 22(12):1387-1398.

[29]Tang, X., Yano, T., Osuga, Y., Matsumi, H., Yano, N., Xu, J., Wada, O., Koga, K., Kugu, K., Tsutsumi, O., et al., 2002. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH releasing hormone antagonist Cetrorelix. J. Clin. Endocrinol. Metab., 87(8):3721-3727.

[30]Völker, P., Gründker, C., Schmidt, O., Schulz, K.D., Emons, G., 2002. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian andendometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am. J. Obstet. Gynecol., 186(2):171-179.

[31]Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V., Baldwin, A.S.Jr., 1998. NF-kappaB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281(5383):1680-1683.

[32]Wu, M., Lee, H., Ballas, R., 1996. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J., 15(17):4682-4690.

[33]Zou, H., Henzel, W.J., Liu, X., Lutschg, A., Wang, X., 1997. A human protein homologues to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90(3):405-413.